lamotrigine has been researched along with Anxiety Neuroses in 17 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the present randomized, single-blind, pilot study was to assess the efficacy of the addition of a second mood stabilizer, either olanzapine or lamotrigine, to lithium in patients with remitted bipolar disorder and comorbid anxiety disorder." | 9.13 | Olanzapine or lamotrigine addition to lithium in remitted bipolar disorder patients with anxiety disorder comorbidity: a randomized, single-blind, pilot study. ( Albert, U; Bogetto, F; Maina, G; Rosso, G, 2008) |
| " Lamotrigine (LTG) is an effective clinical treatment for epilepsy associated with absence seizures." | 7.78 | Lamotrigine ameliorates seizures and psychiatric comorbidity in a rat model of spontaneous absence epilepsy. ( Chen, SD; Huang, HY; Lee, HW; Shaw, FZ, 2012) |
| "Hemophagocytic lymphohistiocytosis is a rare hematological syndrome characterized by excessive and uncontrolled activation of the immune system." | 5.51 | Lamotrigine-induced hemophagocytic lymphohistiocytosis with Takotsubo cardiomyopathy: a case report. ( Martinez, JA; Shen, JP; Zhou, JY, 2019) |
| "The aim of the present randomized, single-blind, pilot study was to assess the efficacy of the addition of a second mood stabilizer, either olanzapine or lamotrigine, to lithium in patients with remitted bipolar disorder and comorbid anxiety disorder." | 5.13 | Olanzapine or lamotrigine addition to lithium in remitted bipolar disorder patients with anxiety disorder comorbidity: a randomized, single-blind, pilot study. ( Albert, U; Bogetto, F; Maina, G; Rosso, G, 2008) |
| " The authors wished to prospectively study the efficacy of lamotrigine as adjunctive or monotherapy in adolescents with bipolar disorder who were experiencing a depressive episode." | 5.12 | An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression. ( Chang, K; Howe, M; Saxena, K, 2006) |
| "The anticonvulsant lamotrigine has been reported to be efficacious and well tolerated as monotherapy in the treatment of bipolar patients as well as in treatment-refractory bipolar disorder." | 5.10 | Lamotrigine as an augmentation agent in treatment-resistant depression. ( Barbee, JG; Jamhour, NJ, 2002) |
| " Lamotrigine (LTG) is an effective clinical treatment for epilepsy associated with absence seizures." | 3.78 | Lamotrigine ameliorates seizures and psychiatric comorbidity in a rat model of spontaneous absence epilepsy. ( Chen, SD; Huang, HY; Lee, HW; Shaw, FZ, 2012) |
| "Patients with borderline personality disorder also appeared to benefit." | 2.48 | Lamotrigine in the treatment of unipolar depression with and without comorbidities: a literature review. ( Ali, R; Zavodnick, AD, 2012) |
| "Hemophagocytic lymphohistiocytosis is a rare hematological syndrome characterized by excessive and uncontrolled activation of the immune system." | 1.51 | Lamotrigine-induced hemophagocytic lymphohistiocytosis with Takotsubo cardiomyopathy: a case report. ( Martinez, JA; Shen, JP; Zhou, JY, 2019) |
| "Topiramate was more likely prescribed for those with comorbid headache or migraine (incident: 335 of 1251 [26." | 1.51 | Antiepileptic Drug Treatment Patterns in Women of Childbearing Age With Epilepsy. ( Faught, E; Fishman, J; Kalilani, L; Kim, H; Thurman, DJ, 2019) |
| "Lamotrigine was discontinued due to suspicion of DRESS; the patient received pulsed intravenous methylprednisolone followed by oral prednisone taper, which resulted in a significant improvement of symptoms." | 1.48 | Lamotrigine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) during primary Epstein-Barr virus (EBV) infection. ( Aljuaid, M; Tawhari, F; Tawhari, I, 2018) |
| "The examined case displays complex partial epilepsy and comorbid mental disorder." | 1.37 | Lamotrigine treatment of a patient affected by epilepsy and anxiety disorder. ( Dadić-Hero, E; Grahovac, T; Ružić, K; Ružić-Baršić, A; Sepić-Grahovac, D, 2011) |
| "For the management of bipolar depression, new data support quetiapine monotherapy as a first-line option." | 1.33 | Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. ( Beaulieu, S; Kennedy, SH; MacQueen, G; McIntyre, RS; O'Donovan, C; Parikh, SV; Sharma, V; Yatham, LN, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 10 (58.82) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Matsuzaka, Y | 1 |
| Urashima, K | 1 |
| Sakai, S | 1 |
| Morimoto, Y | 1 |
| Kanegae, S | 1 |
| Kinoshita, H | 1 |
| Imamura, A | 1 |
| Ozawa, H | 1 |
| Zhou, JY | 1 |
| Martinez, JA | 1 |
| Shen, JP | 1 |
| Tawhari, I | 1 |
| Tawhari, F | 1 |
| Aljuaid, M | 1 |
| Jaffe, RJ | 2 |
| Juneja, NS | 2 |
| Coffey, BJ | 1 |
| Kim, H | 1 |
| Faught, E | 1 |
| Thurman, DJ | 1 |
| Fishman, J | 1 |
| Kalilani, L | 1 |
| Bowen, RC | 1 |
| Balbuena, L | 1 |
| Baetz, M | 1 |
| Parikh, SV | 2 |
| LeBlanc, SR | 1 |
| Ovanessian, MM | 1 |
| Warren, ZE | 1 |
| Sanders, KB | 1 |
| Veenstra-VanderWeele, J | 1 |
| Sepić-Grahovac, D | 1 |
| Grahovac, T | 1 |
| Ružić-Baršić, A | 1 |
| Ružić, K | 1 |
| Dadić-Hero, E | 1 |
| Zavodnick, AD | 1 |
| Ali, R | 1 |
| Huang, HY | 1 |
| Lee, HW | 1 |
| Chen, SD | 1 |
| Shaw, FZ | 1 |
| Barbee, JG | 1 |
| Jamhour, NJ | 1 |
| Stahl, SM | 1 |
| Yatham, LN | 2 |
| Kennedy, SH | 2 |
| O'Donovan, C | 2 |
| Parikh, S | 1 |
| MacQueen, G | 2 |
| McIntyre, R | 1 |
| Sharma, V | 2 |
| Silverstone, P | 1 |
| Alda, M | 1 |
| Baruch, P | 1 |
| Beaulieu, S | 2 |
| Daigneault, A | 1 |
| Milev, R | 1 |
| Young, LT | 1 |
| Ravindran, A | 1 |
| Schaffer, A | 1 |
| Connolly, M | 1 |
| Gorman, CP | 1 |
| Chang, K | 1 |
| Saxena, K | 1 |
| Howe, M | 1 |
| McIntyre, RS | 1 |
| Maina, G | 1 |
| Albert, U | 1 |
| Rosso, G | 1 |
| Bogetto, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Antidepressant Augmentation With Lamotrigine in Patients With Treatment-Resistant Depression[NCT00652171] | Phase 3 | 34 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| A Randomized, Double-blind, Double-dummy, Controlled Trial of Lithium Versus Paroxetine in Subjects With Major Depression Who Have a Family History of Bipolar Disorder or Completed Suicide - a Pilot Study[NCT00400088] | Phase 3 | 2 participants (Actual) | Interventional | 2007-06-30 | Terminated (stopped due to Recruitment difficulties) | ||
| Light-Therapy in the Treatment of the Acute Phase of the Bipolar Type II Depression: Double-Blind, Placebo-Controlled Study to Establish Efficacy and Safety[NCT00590265] | 50 participants (Anticipated) | Interventional | 2008-01-31 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for lamotrigine and Anxiety Neuroses
| Article | Year |
|---|---|
Lamotrigine in the treatment of unipolar depression with and without comorbidities: a literature review.
Topics: Antimanic Agents; Anxiety Disorders; Borderline Personality Disorder; Comorbidity; Depressive Disord | 2012 |
Anticonvulsants as anxiolytics, part 1: tiagabine and other anticonvulsants with actions on GABA.
Topics: Anti-Anxiety Agents; Anticonvulsants; Anxiety Disorders; Carbamazepine; Fructose; GABA Agonists; gam | 2004 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
3 trials available for lamotrigine and Anxiety Neuroses
| Article | Year |
|---|---|
Lamotrigine as an augmentation agent in treatment-resistant depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Bipolar Disorder; Chronic Disease | 2002 |
An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression.
Topics: Adolescent; Antimanic Agents; Anxiety Disorders; Attention Deficit and Disruptive Behavior Disorders | 2006 |
Olanzapine or lamotrigine addition to lithium in remitted bipolar disorder patients with anxiety disorder comorbidity: a randomized, single-blind, pilot study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Anxiety Disorders; Benzodiazepines; Bipolar Disorder; | 2008 |
11 other studies available for lamotrigine and Anxiety Neuroses
| Article | Year |
|---|---|
The effectiveness of lamotrigine for persistent depressive disorder: A case report.
Topics: Antidepressive Agents; Anxiety Disorders; Depressive Disorder, Major; Female; Humans; Lamotrigine; S | 2022 |
Lamotrigine-induced hemophagocytic lymphohistiocytosis with Takotsubo cardiomyopathy: a case report.
Topics: Antipsychotic Agents; Anxiety Disorders; Bone Marrow; Depressive Disorder, Major; Dexamethasone; Fem | 2019 |
Lamotrigine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) during primary Epstein-Barr virus (EBV) infection.
Topics: Anxiety Disorders; Central Nervous System Agents; Drug Hypersensitivity Syndrome; Epstein-Barr Virus | 2018 |
Fourteen-Pound Fluvoxamine-Associated Weight Gain in a Young Woman with Depression and Multiple Anxiety Symptoms.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety | 2018 |
Antiepileptic Drug Treatment Patterns in Women of Childbearing Age With Epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Anxiety Disorders; Comorbidity; Dissociative Disorders; Epilepsi | 2019 |
Lamotrigine reduces affective instability in depressed patients with mixed mood and anxiety disorders.
Topics: Adult; Anxiety Disorders; Depressive Disorder; Female; Humans; Lamotrigine; Male; Middle Aged; Mood | 2014 |
Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).
Topics: Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety Disorders; | 2010 |
Identity crisis involving body image in a young man with autism.
Topics: Adolescent; Anticonvulsants; Anxiety Disorders; Autistic Disorder; Behavior Therapy; Body Dysmorphic | 2010 |
Lamotrigine treatment of a patient affected by epilepsy and anxiety disorder.
Topics: Adult; Anticonvulsants; Anxiety Disorders; Comorbidity; Dose-Response Relationship, Drug; Electroenc | 2011 |
Lamotrigine ameliorates seizures and psychiatric comorbidity in a rat model of spontaneous absence epilepsy.
Topics: Animals; Anticonvulsants; Anxiety Disorders; Comorbidity; Depressive Disorder; Disease Models, Anima | 2012 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007.
Topics: Acute Disease; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Benzodiazepines; Bipo | 2006 |